GlaxoSmithKline gained FDA approval for a modified version of its seasonal flu vaccine FluLaval that has no adjuvant and contains the H1N1 strain. The company expects to begin distributing the vaccine in December and satisfy an order of 7.6 million doses from the government.

Full Story:
Reuters, Bloomberg

Related Summaries